PRNewsWire
08 Jan 2026, 13:45 UTC · 41w ago
Verdict
Headline takes no side. We score VNRX +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
What the story claims
3 claims · scored −1 bearish … +1 bullish
VolitionRx reports that its Nu.Q® Vet Feline assay detected over 80% of feline lymphomas with 100% specificity in a clinical study.
So whatStrong clinical data for a high-accuracy diagnostic tool typically drives positive sentiment and valuation for small-cap biotech firms.
More positive than 93% of claims this week
The company estimates that adding the feline test to its existing canine offering could potentially double its total addressable market in the companion animal space.
Continue reading
5 related stories
Top 2 movers · tap to explore
More positive than 86% of claims this week
VolitionRx intends to leverage existing distribution networks, including reference laboratories and point-of-care platforms, to launch the feline test.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company announced breakthrough clinical data for its feline cancer test, potentially doubling its addressable market in the companion animal space.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2h ago
−96.7%
Price is moving against the score
$0.1890 vs $5.71 close before publication (Jan 7) · not market-adjusted
VNRX chart →
